Uremic Pruritusis also known as chronic kidney disease-associated pruritus (CKD-aP), is a chronic itching that occurs in patients with advanced or end-stage renal disease. The condition can manifest in a single localized area or throughout the body. Uremic Pruritus (UP) management includes pharmacological, non-pharmacological, or combined treatment modalities.
As of now, there are more than 10 drugs in the Uremic Pruritusis pipeline which are under different phases of development.
DelveInsight includes a new addition to its newsletter series that focuses on the Uremic Pruritusis market. The newsletter provides a complete landscape of the Uremic Pruritusis marketspace with current and ongoing clinical trials, pipeline therapies that are in different phases, new therapies that are anticipated to change the game of the Uremic Pruritusis market in the coming years. Explore the rich insights of the Uremic Pruritusis sphere with epidemiological details, treatment therapies, comprehensive features on the latest news and occurring, mergers and collaborations, licensing deals, along with top-level conferences and events.
Do you want to dig into the Uremic Pruritusis market sphere and how pharma companies are working to push the treatment therapies? Download our Newsletter by simply filling up the form towards the right.
Subscribe to our mailing list and stay updated about all the recent innovations in the Chronic Kidney Disease market.
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- R&D in the field
- Top conferences
- News flash
- Recent Research Activities
- Support from International organizations
- Uremic Pruritusis Market Dynamics
- Market insights
- Collaborations and deals in the domain